<DOC>
	<DOCNO>NCT02545985</DOCNO>
	<brief_summary>The aim study assess safety efficacy novel sirolimus-eluting Prolim® stent biodegradable polymer all-comers population .</brief_summary>
	<brief_title>First-in-man Sirolimus-eluting Prolim® Stent Registry</brief_title>
	<detailed_description>Investigators prospectively enrol patient stable coronary artery disease acute coronary syndrome , treat Prolim® stent January December 2013 two interventional cardiology center Poland . Angiographic control plan 12 month , 15 % patient ( randomly choose ) underwent optical coherence tomography analysis . The primary end-point cumulative rate cardiac death , myocardial infarction , target lesion revascularization 12 month .</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>age ≥ 18 year old , stable coronary artery disease ( SCAD ) acute coronary syndrome ( unstable angina UA , nonST elevation myocardial infarction NSTEMI STelevation myocardial infarction STEMI ) sign informed consent inability take dual antiplatelet therapy 12 month , leave ventricular ejection fraction ≤ 30 % , chronic total occlusion , instent restenosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>sirolimus</keyword>
	<keyword>coronary stent</keyword>
	<keyword>Prolim</keyword>
</DOC>